10x Genomics (TXG) Cash from Financing Activities (2018 - 2026)

10x Genomics has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $3.0 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 14.37% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at -$2.5 million (down 129.5% YoY), while the FY2025 annual figure was $6.8 million, down 37.67% from the prior year.
• Cash from Financing Activities came in at $3.0 million for Q2 2026 at 10x Genomics, up from -$8.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q2 2023 to a low of -$8.4 million in Q1 2026.
• Average Cash from Financing Activities over 5 years is $2.3 million, with a median of $2.7 million recorded in 2022.
• Year-over-year, Cash from Financing Activities surged 295.51% in 2025 and plunged 2094.55% in 2026.
• Over 5 years, Cash from Financing Activities stood at $5.0 million in 2022, then climbed by 12.24% to $5.6 million in 2023, then dropped by 19.53% to $4.5 million in 2024, then tumbled by 50.37% to $2.2 million in 2025, then soared by 34.52% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $3.0 million in Q2 2026, -$8.4 million in Q1 2026, and $2.2 million in Q4 2025.